Day: March 13, 2025

Reports Net Investment Income of $2.59 Per Share for Full Year 2024 and Net Asset Value of $19.41 Per Share Continued Share Repurchase Program: Total of 202,357 Shares for an Aggregate Cost of Approximately $3.8 Million Repurchased During Full Year 2024; Accretive to NAV by $0.07 Per Share Announces First Quarter 2025 Regular Quarterly Base Distribution of $0.47 Per Share and Introduces a Quarterly Supplemental Distribution of $0.07 Per Share Merger Agreement with Logan Ridge Aims to Create Meaningful Shareholder Value Via Greater Scale, Enhanced Liquidity, and Improved Operational Efficiencies NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter...

Reports Strong Fourth Quarter Results with Net Investment Income of $0.56 Per Share and a Net Asset Value of $32.04 Per Share Declared a Distribution of $0.36 Per Share for the First Quarter of 2025 Subsequent to Quarter End, LRFC Successfully Exited its Equity Investment in GA Communications, Inc., Further Reducing the Company’s Non-Yielding Equity Portfolio Merger Agreement with Portman Ridge Finance Corporation Aims to Create Meaningful Shareholder Value Via Greater Scale, Enhanced Liquidity, and Improved Operational Efficiencies NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Logan Ridge Finance Corporation (“Logan Ridge”, “LRFC”, the “Company”, “we”, “us” or “our”) (Nasdaq: LRFC) announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 HighlightsTotal investment...

– Fourth Quarter Net Revenue Reaches Quarterly Record of $146.1 million, up 47% Year-over-Year – – Fourth Quarter Net Income of $20.1 million compared to $8.6 million in prior year – – Fourth Quarter Adjusted EBITDA Reaches Quarterly Record of $35.7 million, up from $14.0 million in prior year – – Initiates Full Year 2025 Guidance, including Adjusted EBITDA of between $68 and $72 million representing year-over-year growth of between 21% and 28% – WHITE PLAINS, N.Y., March 13, 2025 (GLOBE NEWSWIRE) — Turtle Beach Corporation (Nasdaq: TBCH), a leading gaming accessories brand, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter HighlightsNet revenue was a record $146.1 million, an increase of 47% compared to the prior year period. Net income was $20.1 million or $0.95 per...

Successfully Concludes Strategic Review with Agreement to Sell Small Cells and Fiber Solutions for $8.5 Billion Results in Crown Castle as the Only Pure-Play, Publicly-Traded US Tower Company Increases Capital Efficiency with Updated Capital Allocation Framework, Including Anticipated New Dividend Policy and Proposed Approximately $3.0 Billion Share Repurchase Program HOUSTON, March 13, 2025 (GLOBE NEWSWIRE) — Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or “Company”) today reported results for the full year ended December 31, 2024, as reflected in the table below.  Actual Previous2024OutlookMidpoint(b) ActualComparedto PreviousOutlookMidpoint(dollars in millions, except per share amounts) 2024 2023 Change % ChangeSite rental revenues $6,358 $6,532 $(174) (3)% $6,340 $18Net income (loss) $(3,903) $1,502 $(5,405) (360)% $1,020 $(4,923)Net...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive final data from randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinoma On track to report biomarker and final overall survival data from open label phase 2a clinical trial per protocol analysis in non-small cell lung cancer (NSCLC) patients who received two administrations of CAN-2409, expected in Q1 2025 On track to report biomarker and initial survival data from ongoing phase 1b trial evaluating multiple doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG), expected in Q4 2025  Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway,...

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 (“Q3 FY2025”) and to date in 2025, HeartSciences has seen material progress towards FDA submissions of our products and there have been significant positive developments in the AI-ECG field. A summary of the current status and key business highlights for Q3 FY2025 include:AI-ECG presents a generational opportunity to modernize...

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2024 and recent business highlights. The Company also announced the completion of a strategic portfolio review resulting in...

IRVINE, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the fourth quarter and fiscal year ended January 3, 2025. HighlightsReported revenue of $104 million, which includes $80 million of Shimmick Projects revenue, for Q4 2024, and revenue of $480 million, which includes $356 million of Shimmick Projects revenue, for FY2024 Reported liquidity of $100 million as of January 3, 2025, reflecting the positive outcomes of the Transformation Plan implemented in 2024. Further and on March 12, 2025, we entered into a new credit agreement which replaced the MidCap Revolving Credit Facility and provides a total commitment of $15 million. Recognized a net loss of $38 million and Adjusted EBITDA of $(27) million for Q4 2024, largely attributable...